Friday, 16 October 2026European Markets

LISGRAFICA Stock Soars 33% In 21 Sessions: Is It A Buy?

Loading stream...

(VIANEWS) - LISGRAFICA (PSI: LIG.LS) experienced a dramatic jump in share price over 21 sessions from EUR0.01 to EUR0.01 by 15:34 EST on Friday - increasing 33.333% between EUR0.01 and EUR0.01, before experiencing an immediate downturn; its PSI dropped 0.13% following previous upward trends before closing on EUR0.01, 36.84% below its 52-week high of EUR0.01

About LISGRAFICA

Lisgrafica - Impressao e Artes Graficas, S.A. is an Agualva-Cacem-based printing company established in 1973 that provides various printing services ranging from magazine, newspaper and supplement printing, catalog and brochure creation and telephone directory production. A subsidiary of Rasografica - Comercio e Servicos Graficos S.A. since 1974, Lisgrafica has provided high-quality solutions for over four decades now.

Yearly Analysis

LISGRAFICA stock currently trades at EUR0.01, above its 52-week high of EUR0.01. This indicates that LISGRAFICA shares have performed exceptionally over the past year. P/E Ratio LISGRAFICA's P/E Ratio stands at 4.29, which is low compared to its industry peers' average of 23.33. This indicates that LISGRAFICA stock may be undervalued relative to its peers within its industry. Dividend Yield LISGRAFICA currently boasts an anemic dividend yield, which falls well short of its industry average of 1.87%. As such, LISGRAFICA may not be an appropriate choice for income investors. LISTAGRAFICA's EPS growth over the last three years is estimated to be in excess of 25%, which indicates strong earnings growth at the company. Revenue GrowthHistorically, Grafica's revenues have experienced steady annual increases of 20% or higher. This indicates a successful trend of steady revenue expansion for this company. Based on this information, LISGRAFICA appears to be performing strongly, boasting a low price-earnings ratio and solid growth in earnings and revenues. Unfortunately, however, its low dividend yield may make it less appealing for income investors. Overall, investors should carefully consider LISGRAFICA's fundamentals along with industry developments and market sentiment when making investment decisions about LISGRAFICA stock.

Technical Analysis

Moving AverageLOS GRAFICA's current price of EUR1.50 is significantly above its 50-day moving average of EUR1.36 and significantly greater than its 200-day moving average of EUR1.28 - this indicates a strong upward trend over recent months in its stock price. VolumeLISGRAFICA's trading volume of 512,000 shares represents an over-99.93% decline compared to its average volume of 296,980, suggesting low interest for this stock or that investors are waiting for better entry points before buying in. VolatilityLISGRAFICA has seen high volatility recently, with positive 8.33% intraday variation last week and negative 2.08% change last month, and positive 17.23% change quarter over quarter. Such volatility could present buyers and sellers alike with buying and selling opportunities should the stock break free from its recent price fluctuations. LISGRAFICA had an 8.33% weekly average volatility over the last week, 20.67% over last month and 17.23% over last quarter - all levels which indicate potential for price swings that can present opportunities for traders and investors to make successful trades. Overall, LISGRAFICA's recent performance suggests a promising upward trend; however, due to low trading volume and high volatility levels it may present potential challenges to investors. As with any investment it is essential to conduct thorough research and analysis prior to making any definitive decisions.

Quarter Analysis

Based on this data, year-on-year quarterly revenue growth has fallen by 12.18% year over year to 9.78M for this company's trailing twelve month revenue total compared to 10.26M last year. This indicates that revenue growth has decreased since 2017. Investors should keep an eye on a company's revenue growth as an important measure of its financial health and future prospects. A decrease in revenue growth may signal challenges within operations or market conditions; investors are advised to conduct further analysis in order to understand why this revenue decline has occurred, evaluate overall financial performance and examine future growth potential of their chosen investment vehicle.

Equity Analysis

LISGRAFICA currently boasts an earnings per share (EPS) figure of EUR-0.026 over its trailing twelve month period, suggesting it had negative earnings per share for that timeframe. As an investor, it is vital to evaluate a company's profitability as this can impact dividend payments, investments made and expansion efforts undertaken by them. Negative earnings per share (EPS) is often seen as an early warning signal that indicates losses at a company, which should prompt potential investors to investigate further. But it's also essential that other financial metrics, such as revenue growth and operating margins are taken into consideration to provide a complete view of financial health at any particular firm. Potential investors of LISGRAFICA should closely study its earnings reports and financial statements in order to assess its profitability, and assess if it presents an appropriate investment opportunity.

More news about LISGRAFICA (LIG.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com